Who should not use Inspra?

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, those with severe renal impairment (eGFR 5.0 mmol/L). It should also be avoided in patients taking other potassium‑sparing agents without careful monitoring.

Inspra

Active Ingredient:: Eplerenone
Origin:: EU

Inspra (Eplerenone)

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients.
GNH India supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Nv/Sa

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Inspra, an aldosterone antagonist, is employed in cardiovascular conditions that involve excess aldosterone activity.
Hypertension: lowers blood pressure by promoting sodium excretion and potassium retention.
Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations by decreasing cardiac remodeling.
Post‑myocardial infarction: reduces the risk of cardiovascular death and heart failure when added to standard therapy.

How It Works

Eplerenone selectively blocks mineralocorticoid receptors in the distal nephron, preventing aldosterone from binding. This antagonism reduces sodium reabsorption and promotes natriuresis while retaining potassium, leading to decreased extracellular fluid volume and lower blood pressure. The blockade also attenuates aldosterone‑mediated cardiac remodeling, contributing to its benefits in heart failure.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

Hyperkalemia: elevated blood potassium levels.
Hyponatremia: low sodium concentration.
Dizziness or light‑headedness.
Headache.
Fatigue.
Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects

Severe hyperkalemia leading to cardiac arrhythmia.
Acute kidney injury or worsening renal function.
Allergic reactions including rash, pruritus, or angioedema.
Hormonal disturbances causing menstrual irregularities.
Elevated serum creatinine.
Hepatic enzyme abnormalities.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

Monitor serum potassium and renal function regularly, especially in patients with renal impairment.
Avoid use in patients with hyperkalemia or severe renal dysfunction.
Caution in individuals taking other potassium‑sparing agents or supplements.
Adjust dose or discontinue if significant increases in creatinine occur.
Use with caution in the elderly due to altered pharmacokinetics.
Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Eplerenone may interact with several concomitant medications.

Major Interactions (Avoid)

Potassium supplements or potassium‑sparing diuretics: risk of severe hyperkalemia.
ACE inhibitors or ARBs: additive effect on potassium and renal function.
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase eplerenone plasma levels.

Moderate Interactions (Monitor Closely)

NSAIDs: may reduce renal clearance and increase potassium.
Digoxin: heightened risk of digoxin toxicity with elevated potassium.
Cyclosporine: may potentiate renal impairment.
Thiazide diuretics: can counteract potassium‑sparing effect, requiring monitoring.

Frequently Asked Questions

Inspra contains the active ingredient eplerenone and is prescribed to manage high blood pressure (hypertension) and to treat heart failure with reduced ejection fraction. It is also used after a myocardial infarction to lower the risk of cardiovascular death and subsequent heart failure when added to standard post‑MI therapy.

Eplerenone selectively blocks mineralocorticoid (aldosterone) receptors in the distal tubules of the kidney. By preventing aldosterone binding, it reduces sodium reabsorption and promotes potassium retention, leading to increased urine output, lower blood volume, and reduced blood pressure. The blockade also mitigates aldosterone‑driven cardiac remodeling, benefiting heart‑failure patients.

The dosage of Inspra is individualized by the prescribing clinician based on the patient’s condition, renal function, and serum potassium levels. The prescriber determines the appropriate starting dose and any subsequent adjustments, following current clinical guidelines and monitoring parameters.

The safety of eplerenone during pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before using Inspra.

To place an order, submit an enquiry on the Inspra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both eplerenone (Inspra) and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Spironolactone may have a broader hormonal profile, leading to a higher incidence of endocrine‑related adverse events, while eplerenone often offers a better tolerability profile for many patients.

Inspra tablets should be stored at ambient temperature below 25 °C. Keep them in the original container, protect from moisture, heat, and direct sunlight. Do not freeze or refrigerate the tablets, and keep them out of reach of children.

Inspra is taken orally as a tablet, usually with a full glass of water. It can be taken with or without food, but consistency with meals helps maintain stable absorption. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most critical safety concerns include hyperkalemia, which can cause cardiac arrhythmias, and worsening renal function, indicated by rising serum creatinine. Patients should be monitored regularly for electrolyte disturbances and kidney function, especially when initiating therapy or adjusting concomitant medications.

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, those with severe renal impairment (eGFR <30 mL/min/1.73 m²), and patients with hyperkalemia (serum potassium >5.0 mmol/L). It should also be avoided in patients taking other potassium‑sparing agents without careful monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.